Xavier Janssen

For Corporates
Insights into Healthcare M&A: Q3 2024 Trends
Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Related Team
Xavier Janssen

Xavier Janssen is a Senior Managing Director of Institutional Equities at Leerink Partners.

Mr. Janssen joined the Firm in 2004 and brings over 30 years of experience in equity markets. Prior to joining Leerink Partners, he was a Director / Swiss Country Head at Deutsche Bank responsible for U.S. equity sales trading, trading, derivatives and institutional research sales. Before Deutsche Bank, Mr. Janssen was at ING Barings Furman Selz where he was responsible for institutional research sales into Europe.

Mr. Janssen earned his B.A. in English and Political Science from Hobart and William Smith Colleges and his M.B.A. from Babson F.W. Olin Graduate School of Business.

Partner With Us

Contact Us